DNX, XLp Partner to Develop Long-Acting Biopharmaceuticals

DNX Biopharmaceuticals, Inc. and XL-protein GmbH (XLp) have entered a strategic collaboration for the development and commercialization of novel, long-acting biopharmaceutical products. XLp will contribute its half-life extension platform technology (PASylation) and certain molecules that have completed in vivo efficacy and preclinical studies, and DNX will add its pipeline of molecules for development and commercialization to address a range of unmet needs in immunology, metabolism and ophthalmology. Financial terms were not disclosed.

Half-life extension is a critical aspect of developing successful proteins. The PASylation platform is designed to offer improved half-life, pharmacokinetics, pharmacodynamics, bioavailability, solubility and overall enhanced patient compliance and safety.

“We are pleased to be partnering with XL-protein on the development of new molecules specifically designed to improving the lives of patients, while simultaneously helping to alleviate the clinical burden,” said Dr. Rajiv Datar, chief executive of DNX. “By combining DNX’s 250+ person-years of experience of biologics process development, clinical development and GMP manufacturing expertise with XLp’s revolutionary PASylation platform, we hope to ‘Make Good Drugs Great,’ and to delivering more gain and less pain to patients.”

“Working with DNX to create a range of novel long-acting biopharmaceuticals that will provide benefits to patients and to the healthcare services by reducing clinical burden is exciting and satisfying,” said Claus Schalper, managing director of XL-protein. “Our team shares a common passion with DNX to ‘Making Good Drugs Even Greater’ by contributing our half-life extension / drug delivery technology to support successful product development and commercialization.”